公开(公告)号：US11369603B2

公开(公告)日：2022-06-28

申请号：US16605240

申请日：2018-04-17

Applicant: Novartis AG

Inventor： Donald Johns ,  Klaus Kucher ,  Judit Sovago

IPC: A61K31/501 ,  A61P25/26 ,  A61K31/137 ,  A61K31/165 ,  A61K31/19 ,  A61K31/4458 ,  A61K31/522

Abstract: The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.

公开(公告)号：US20210379062A1

公开(公告)日：2021-12-09

申请号：US17284011

申请日：2019-10-10

Applicant: Novartis AG

Inventor： Donald Johns ,  Judit Sovago

IPC: A61K31/501 ,  A61K31/198 ,  A61K31/4745 ,  A61K31/4045 ,  A61K31/277 ,  A61K31/165 ,  A61K31/426 ,  A61P25/26

Abstract: The invention relates to the use of Compound (I), as defined herein, or pharmaceutically acceptable salt thereof, in the treatment of excessive daytime sleepiness associated with Parkinson's disease.

公开(公告)号：US11311525B2

公开(公告)日：2022-04-26

申请号：US15686919

申请日：2017-08-25

Applicant: Novartis AG

Inventor： Markus Fendt ,  Dominik Feuerbach ,  Sjoerd Johannes Finnema ,  Christer Halldin ,  Donald Johns ,  Cristina Lopez-Lopez ,  Kevin Hall McAllister ,  Judit Sovago ,  Markus Weiss

IPC: A61K31/444 ,  A61K9/00 ,  A61K45/06 ,  A61K47/02 ,  A61K31/08 ,  A61K31/135

Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.